Effects of abacavir administration on structural and functional markers of platelet activation

AIDS

Volumn 29, Issue 17, 2015, Pages 2309-2313

  Trevillyan, Janine M ^a,b   Arthur, Jane F ^a   Jing, Jing ^a   Andrews, Robert K ^a   Gardiner, Elizabeth E ^a   Hoy, Jennifer F ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b Faculty of Medicine   (Australia)

Author keywords

abacavir; cardiovascular disease; coagulation; HIV; platelet activation

Indexed keywords

ABACAVIR; ADENOSINE DIPHOSPHATE; BETA3 INTEGRIN; EMTRICITABINE; GLYCOPROTEIN VI; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROSTAGLANDIN E1; PROTEINASE INHIBITOR; TENOFOVIR; VASODILATOR STIMULATED PHOSPHOPROTEIN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; MALE; OPEN STUDY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TREATMENT DURATION; DRUG EFFECTS; HIV INFECTIONS; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION;

EID: 84957616065     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000848     Document Type: Article

References (16)

1. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61:441-447.
2. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multicohort collaboration. Lancet 2008; 371:1417-1426.
3. Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44:139-147.
4. Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 2009; 20:143-149.
5. Al-Tamimi M, Arthur JF, Gardiner E, Andrews RK. Focusing on plasma glycoprotein VI. Thromb Haemost 2012; 107:648-655.
6. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb Haemost 2012; 10:167-176.
7. Baum PD, Sullam PM, Stoddart CA, McCune JM. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS 2011; 25:2243-2248.
8. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008; 117:743-753.
9. Bautista AP, Buckler PW, Towler HM, Dawson AA, Bennett B. Measurement of platelet life-span in normal subjects and patients with myeloproliferative disease with indium oxine labelled platelets. Br J Haematol 1984; 58:679-687.
10. Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH, et al. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2009; 53:1532-1538.
11. Falcinelli E, Francisci D, Belfiori B, Petito E, Guglielmini G, Malincarne L, et al. In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. Thromb Haemost 2013; 110:349-357.
12. Satchell CS, O'Halloran JA, Cotter AG, Peace AJ, O'Connor EF, Tedesco AF, et al. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. J Infect Dis 2011; 204:1202-1210.
13. Bigalke B, Geisler T, Stellos K, Langer H, Daub K, Kremmer E, et al. Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Am Heart J 2008; 156:193-200.
14. O'Halloran JA, Dunne E, Tinago W, Denieffe S, Kenny D, Mallon PWG. Effect of Switch from Abacavir to Tenofovir DF on Platelet Function Markers: A SWIFT Trial Substudy. In: Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA; 2014.
15. Yakushkin VV, Zyuryaev I T, Khaspekova S G, Sirotkina O V, Ruda M Y, Mazurov A V. Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome. Platelets 2011; 22:243-251.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.